Dr. Joseph Pidala, MD, PhD
Claim this profileMoffitt Cancer Center
Studies Graft-versus-Host Disease
Studies Blood Cancers
13 reported clinical trials
26 drugs studied
Area of expertise
1Graft-versus-Host Disease
HLA-A negative
HLA-A positive
RB1 positive
2Blood Cancers
T315I positive
Stage I
Stage II
Affiliated Hospitals
Clinical Trials Joseph Pidala, MD, PhD is currently running
Extended vs Short-Term Abatacept Dosing
for Graft-versus-Host Disease
This is a multicenter randomized, double blind, Phase 2 trial for patients receiving transplants from 7 of 8 HLA matched donors, in which an extended dosing regimen of abatacept, and a short-term dosing regimen + placebo, when added to standard calcineurin inhibitor + methotrexate-based prophylaxis, will be compared for their ability to improve outcomes in patients with a minimum follow-up of one year post-transplant. All patients will receive 4 doses of abatacept (Days -1, +5, +14, +28). Prior to the fifth dose, patients will be randomly assigned to the 4-dose abatacept arm and receive 4 doses of placebo or 8-dose abatacept arm and receive 4 more doses of abatacept. The primary endpoint of the study will be severe AGVHD-free, severe CGVHD-free, relapse-free survival (SGRFS). The study will end when the last patient has reached 2 years after transplant. Results will first be calculated and the study unblinded when the last patient has reached one year post-transplant.
Recruiting0 awards Phase 2
Gamma Delta T-Cell Infusion
for Acute Myeloid Leukemia
The purposes of the study are to determine the maximum tolerated dose (MTD) and effectiveness of Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells administered as a single infusion after an allogeneic hematopoietic cell transplant (alloHCT) to treat patients with Acute Myeloid Leukemia (AML).
Recruiting1 award Phase 1
More about Joseph Pidala, MD, PhD
Clinical Trial Related2 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Joseph Pidala, MD, PhD has experience with
- Medical Chart Review
- Biospecimen Collection
- Quality-of-Life Assessment
- Donor Search Prognosis Score
- Optical Coherence Tomography
- Spirometry
Breakdown of trials Joseph Pidala, MD, PhD has run
Graft-versus-Host Disease
Blood Cancers
Leukemia
Acute Myeloid Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Joseph Pidala, MD, PhD specialize in?
Joseph Pidala, MD, PhD focuses on Graft-versus-Host Disease and Blood Cancers. In particular, much of their work with Graft-versus-Host Disease has involved HLA-A negative patients, or patients who are HLA-A positive.
Is Joseph Pidala, MD, PhD currently recruiting for clinical trials?
Yes, Joseph Pidala, MD, PhD is currently recruiting for 7 clinical trials in Tampa Florida. If you're interested in participating, you should apply.
Are there any treatments that Joseph Pidala, MD, PhD has studied deeply?
Yes, Joseph Pidala, MD, PhD has studied treatments such as Medical Chart Review, Biospecimen Collection, Quality-of-Life Assessment.
What is the best way to schedule an appointment with Joseph Pidala, MD, PhD?
Apply for one of the trials that Joseph Pidala, MD, PhD is conducting.
What is the office address of Joseph Pidala, MD, PhD?
The office of Joseph Pidala, MD, PhD is located at: Moffitt Cancer Center, Tampa, Florida 33612 United States. This is the address for their practice at the Moffitt Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.